31 Aug

What Happens When A Farmer Attends a Food Science Convention?

The story could start with a farmer and a food scientist walk into a bar…or a restaurant…or a grocery store…or the Food Expo at IFT18: A Matter of Science and Food. Although they stand at opposite ends of the food chain, their topic of conversation is food - sustainability, security, waste and innovation.

GMO Answers volunteer expert and farmer Katie Pratt joined GMO Answers at their booth during the Institute of Food Technologists (IFT) Convention in Chicago in July. Katie and her husband, Andy, are seventh generation farmers raising farm kids, corn, soybeans, and seed corn with Andy’s family in north central Illinois.

She talked to many food scientists, nutritionists, technologists, and marketing professionals. During the show, Katie did a Facebook Live video for GMO Answers, with some initial thoughts about her conversations and engagements.

After the show, and with some time to look back and reflect on her experience, she wrote a blog post for the GMO Answers Medium page. Her main theme: Farmers, scientists and researchers have a message for you: GMOs are safe! But this message is getting muddled due to a lack in science literacy.

Her three main takeaways:

  • Food scientists support science. The majority of the people who stopped at the GMO Answers booth did so to say, “Thanks for being here. We need people talking about GMOs, about science.”
  • Crafting a scientific message that can be - should be - heard by their marketing counterparts is a great source of frustration for food scientists.
  • The discussion of sustainability, food insecurity and food waste are everywhere! From small-town USA to the developing world, our planet is hungry and our ability to understand science affects our ability to innovate, to discover solutions to very timely problems.

Ultimately, science literacy must make a comeback in our schools, in our universities, in our daily conversations. Because when we understand the world around us, be it a field, a pasture, a laboratory or a bar, our ability to do better grows.

For more about GMOs, please visit the GMO Answers website.

 

 

31 Aug

Grants for joint actions with Member States to support access to Alternative Dispute Resolution mechanisms for consumers

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: CONS-ADR-2018Pillar: Consolidate consumer rightsOpening Date: Deadline: Tue, 4 Dec 2018 17:00:00 (Brussels local time)Modification Date: Thu, 30 Aug 2018Latest information: The submission session is now available for: CONS-ADR-2018(CONS-JA)

31 Aug

E-Scape Bio Names Julie Anne Smith President & CEO

Julie Anne Smith has joined E-Scape Bio as president and CEO of the San Francisco company. She has also joined the neurological drug developer’s board of directors. Before coming E-Scape, Smith was president and CEO of Menlo Park, CA-based Nuredis. Smith’s experience also includes executive posts at Raptor Pharmaceuticals and Enobia Pharmaceuticals. Last year, E-Scape raised $63 million in a Series A round of investment. The company’s lead program, an experimental treatment for central nervous system-related lysosomal storage disorders, is expected to enter clinical trials in 2019.

UNDERWRITERS AND PARTNERS

          

          

            

30 Aug

STARTS Talk: Human Agency In The Robotic World, lecture by Alexander Mankowsky – 19 September 2018, Brussels, BOZAR

[Source: Research & Innovation] How is artificial intelligence (AI) influencing tomorrow’s mobility solutions? How can the community be optimized by machine support and, above all, how does this affect people?
These are the central questions discussed by Alexander Mankowsky, futurologist at the automotive company Daimler.

Under the title ‘Human Agency In A Robotic World’, Mankowsky will discuss the design requirements needed to retain or enhance human agency when dealing with devices, using the autonomous car as an example.

Within the frame of the EC initiative ‘STARTS’, this event is organised by Gluon in collaboration with BOZAR lab. Entry tickets on sale as indicated at BOZAR’s web-site.

30 Aug

Sutro Biopharma, Arvinas Are Latest to Tee Up Biotech IPOs

The biotech IPO train is rolling on without slowing as we head into a holiday weekend. The latest to lay the groundwork to go public are Sutro Biopharma and Arvinas, which both want Wall Street’s help to back human trials of experimental cancer drugs.

South San Francisco, CA-based Sutro set a preliminary $75 million target in the IPO paperwork it filed on Thursday. Sutro has applied for a listing on the Nasdaq under the stock symbol “STRO.”

Sutro will use the IPO cash to fund its two lead cancer drugs, STRO-001 and STRO-002. Both are antibody drug conjugates, a type of Read more »

UNDERWRITERS AND PARTNERS

          

          

            

30 Aug

National Immunization Awareness Month is Timely Reminder of Modern Marvel of Vaccines

August marks National Immunization Awareness Month – a time to take inventory on where we stand, and recognize how far we’ve come, in advancing breakthrough vaccines designed to protect the world’s population. However, despite the clear societal and economic benefits that come with common vaccinations like a flu shot, distorted facts and misinformation about immunization often stand between these extraordinary products and the populations that urgently need them. Regardless of a greater portion of society agreeing that the benefits outweigh the risks, year-round efforts to ensure individuals across the globe are educated with the facts on vaccine safety and effectiveness are more important than ever.

And the facts are now beyond doubt. One estimate found that between 2011 and 2020, vaccines will have averted over 23 million deaths in low-income countries. What’s more, according to the CDC, vaccines are responsible for saving the lives of more than 730,000 American children between 1994-2013. During this same period, more than 320 million childhood illnesses were prevented in the U.S. alone.

But it’s not just children who benefit from vaccines. Men and women of all ages should make sure they are up to date – especially as individuals age and their immune systems weaken. In the U.S., the Alliance for Aging Research found that between 50,000 and 90,000 adults die annually from vaccine-preventable diseases or their complications. Each one of those deaths is a terrible tragedy that could easily be avoided with more widespread vaccination.

Beyond the impact on our lives and health, vaccines also have a tremendous positive economic impact. American businesses lose billions of dollars in lost productivity each year because of employees falling ill from sicknesses that vaccines could have helped prevent. In fact, one estimate predicted that 11 million workers would become sick with the flu during the 2018 winter season, costing their employers over $9 billion in sick leave. Another study found that the vaccination of children born in the United States in 2009 is projected to generate $184 billion in lifetime social value – that’s about $45,000 per child.

The data speaks for itself: from both an economic and public health standpoint, vaccines have the ability to shape and change the world. Take polio for example. An outbreak in 1952 took the lives of 3,000 Americans, paralyzing another 21,000 in that same year. Families were broken, communities were devastated, and our country lived in fear. What seemed like an unbeatable challenge, however, was no match for science. Years of R&D and sleepless nights led many brilliant scientists to a vaccine for the virus by 1955. In 1979, polio, once our nation’s most feared disease, was officially eliminated in the United States.

Shingles is another condition that we now have the tools to conquer. This painful rash, often described as debilitating and intense, can last for weeks, and feel like an eternity for many patients. But the past few years have brought welcome news. The CDC now recommends two vaccines for adults age 50 years or older, and these modern marvels are highly effective at reducing the severity of shingles pain which is an incredible step forward in the fight against this debilitating illness.

It’s also encouraging to see researchers and scientists’ race against time to prevent emerging viral diseases like Zika, Ebola, or Middle East Respiratory Syndrome (MERS) from spreading and thus causing an unpredictable outbreak. As Dr. Michael Ryan of the World Health Organization recently explained, new tools and resources are being used to control Ebola as we speak. After spending time on the ground with vaccination teams and families in the Democratic Republic of Congo, Dr. Ryan added, “for the first time in my experience, I saw hope in the face of Ebola and not terror.”

Today, more than 260 vaccines are in development to both prevent and treat diseases. The pipeline includes a vaccine to prevent HIV and a therapy focused on combating Alzheimer’s, among others. The science is incredible, but as a society we must do our part. Talk to your loved ones – family, friends, colleagues, or peers – and spread the word about the benefits of getting vaccinated. For ourselves and for our children and grandchildren, we can’t afford to do otherwise.

Phyllis Arthur is the Vice President for Infectious Diseases and Diagnostics Policy at BIO, responsible for working with member companies in vaccines, molecular diagnostics and bio-defense on policy, legislative and regulatory issues.

29 Aug

Ex-Buckeyes assistant Zach Smith: ‘Time 4 u all 2 face the damage ur causing’

Former Ohio State assistant coach Zach Smith took to Twitter on Wednesday to break his silence since the completion of the university’s investigation, …

29 Aug

BUILDING A LOW-CARBON, CLIMATE RESILIENT FUTURE: SECURE, CLEAN AND EFFICIENT ENERGY

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: H2020-LC-SC3-2018-2019-2020Pillar: Societal ChallengesPlanned Opening Date: Deadline: Tue, 5 Feb 2019 17:00:00 (Brussels local time)Modification Date: Wed, 29 Aug 2018Latest information: All 47 proposals invited to the second stage of the two-stage topics of this call have been submitted by the call deadline (28 August 2018). The detail per topic is:
-LC-SC3-RES-4-2018 (RIA): 21 proposals
-LC-SC3-RES-11-2018 (RIA): 26 proposals

28 Aug

Bristol Promotes Christopher Boerner to Chief Commercial Officer

Bristol-Myers Squibb (NYSE: BMY) has promoted Christopher Boerner to chief commercial officer. Boerner had been head of Bristol’s U.S. commercial organization, a post he has held since joining the New York-based pharmaceutical giant in 2015. His experience also includes positions at Seattle Genetics (NASDAQ: SGEN), Dendreon, and Genentech. Boerner succeeds Murdo Gordon, who left Bristol earlier this month to join Amgen (NASDAQ: AMGN) as executive vice president of global commercial operations.

UNDERWRITERS AND PARTNERS

          

          

            

28 Aug

Cybersecurity

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: H2020-SU-ICT-2018-2020Pillar: Industrial LeadershipOpening Date: Deadline: Tue, 28 Aug 2018 17:00:00 (Brussels local time)Modification Date: Tue, 28 Aug 2018Latest information: CallH2020-SU-ICT-2018 has closed on 28 August 2018.
51proposals have been submitted to topic SU-ICT-01-2018 (IA).